Understanding the Needs and Lived Experiences of Patients With Graft-Versus-Host Disease: Real-World European Public Social Media Listening Study.

GVHD graft-versus-host disease infoveillance patient journey quality of life real-world evidence social media social media listening

Journal

JMIR cancer
ISSN: 2369-1999
Titre abrégé: JMIR Cancer
Pays: Canada
ID NLM: 101666844

Informations de publication

Date de publication:
10 Nov 2023
Historique:
received: 18 10 2022
accepted: 04 08 2023
revised: 14 02 2023
medline: 10 11 2023
pubmed: 10 11 2023
entrez: 10 11 2023
Statut: epublish

Résumé

Graft-versus-host disease (GVHD) is the major cause of short- and long-term morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Treatment options beyond corticosteroid therapy remain limited, and prolonged treatment often leads to impaired quality of life (QoL). A better understanding of the needs and experiences of patients with GVHD is required to improve patient care. The aim of this study is to explore different social media (SM) channels for gathering and analyzing the needs and experiences of patients and other stakeholders across 14 European countries. We conducted a retrospective analysis of SM data from the public domain. The Talkwalker social analytics tool collected data from open-access forums, blogs, and various social networking sites using predefined search strings. The raw data set derived from the aggregator tool was automatically screened for the relevancy of posts, generating the curated data set that was manually reviewed to identify posts that fell within the predefined inclusion and exclusion criteria. This final data set was then used for the deep-dive analysis. A total of 9016 posts relating to GVHD were identified between April 2019 and April 2021. Deduplication and relevancy checks resulted in 325 insightful posts, with Twitter contributing 250 (77%) posts; blogs, 49 (15%) posts; forums, 13 (4%) posts; Facebook, 7 (2%) posts; and Instagram and YouTube, 4 (1%) posts. Patients with GVHD were the primary stakeholders, contributing 63% of all SM posts. In 234 posts, treatment was the most discussed stage of the patient journey (68%), followed by symptoms (33%), and diagnosis and tests (21%). Among treatment-related posts (n=159), steroid therapy was most frequently reported (54/159, 34%). Posts relating to treatment features (n=110) identified efficacy (45/110, 41%), side effects (38/110, 35%), and frequency and dosage (32/110, 29%), as the most frequently discussed features. Symptoms associated with GVHD were described in 24% (77/325) of posts, including skin-related conditions (49/77, 64%), dry eyes or vision change (13/77, 17%), pain and cramps (16/77, 21%), and fatigue or muscle weakness (12/77, 16%). The impacts of GVHD on QoL were discussed in 51% (165/325) of all posts, with the emotional, physical and functional, social, and financial impacts mentioned in 69% (114/165), 50% (82/165), 5% (8/165), and 2% (3/165) of these posts, respectively. Unmet needs were reported by patients or caregivers in 24% (77/325) of analyzed conversations, with treatment-related side effects being the most common (35/77, 45%) among these posts. SM listening is a useful tool to identify medical needs. Treatment of GVHD, including treatment-related side effects, as well as its emotional and physical impact on QoL, are the major topics that GVHD stakeholders mention on SM. We encourage a structured discussion of these topics in interactions between health care providers and patients with GVHD. Not applicable.

Sections du résumé

BACKGROUND BACKGROUND
Graft-versus-host disease (GVHD) is the major cause of short- and long-term morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Treatment options beyond corticosteroid therapy remain limited, and prolonged treatment often leads to impaired quality of life (QoL). A better understanding of the needs and experiences of patients with GVHD is required to improve patient care.
OBJECTIVE OBJECTIVE
The aim of this study is to explore different social media (SM) channels for gathering and analyzing the needs and experiences of patients and other stakeholders across 14 European countries.
METHODS METHODS
We conducted a retrospective analysis of SM data from the public domain. The Talkwalker social analytics tool collected data from open-access forums, blogs, and various social networking sites using predefined search strings. The raw data set derived from the aggregator tool was automatically screened for the relevancy of posts, generating the curated data set that was manually reviewed to identify posts that fell within the predefined inclusion and exclusion criteria. This final data set was then used for the deep-dive analysis.
RESULTS RESULTS
A total of 9016 posts relating to GVHD were identified between April 2019 and April 2021. Deduplication and relevancy checks resulted in 325 insightful posts, with Twitter contributing 250 (77%) posts; blogs, 49 (15%) posts; forums, 13 (4%) posts; Facebook, 7 (2%) posts; and Instagram and YouTube, 4 (1%) posts. Patients with GVHD were the primary stakeholders, contributing 63% of all SM posts. In 234 posts, treatment was the most discussed stage of the patient journey (68%), followed by symptoms (33%), and diagnosis and tests (21%). Among treatment-related posts (n=159), steroid therapy was most frequently reported (54/159, 34%). Posts relating to treatment features (n=110) identified efficacy (45/110, 41%), side effects (38/110, 35%), and frequency and dosage (32/110, 29%), as the most frequently discussed features. Symptoms associated with GVHD were described in 24% (77/325) of posts, including skin-related conditions (49/77, 64%), dry eyes or vision change (13/77, 17%), pain and cramps (16/77, 21%), and fatigue or muscle weakness (12/77, 16%). The impacts of GVHD on QoL were discussed in 51% (165/325) of all posts, with the emotional, physical and functional, social, and financial impacts mentioned in 69% (114/165), 50% (82/165), 5% (8/165), and 2% (3/165) of these posts, respectively. Unmet needs were reported by patients or caregivers in 24% (77/325) of analyzed conversations, with treatment-related side effects being the most common (35/77, 45%) among these posts.
CONCLUSIONS CONCLUSIONS
SM listening is a useful tool to identify medical needs. Treatment of GVHD, including treatment-related side effects, as well as its emotional and physical impact on QoL, are the major topics that GVHD stakeholders mention on SM. We encourage a structured discussion of these topics in interactions between health care providers and patients with GVHD.
TRIAL REGISTRATION BACKGROUND
Not applicable.

Identifiants

pubmed: 37948101
pii: v9i1e42905
doi: 10.2196/42905
pmc: PMC10674148
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e42905

Informations de copyright

©Zinaida Perić, Grzegorz Basak, Christian Koenecke, Ivan Moiseev, Jyoti Chauhan, Sathyaraj Asaithambi, Alexandros Sagkriotis, Sibel Gunes, Olaf Penack. Originally published in JMIR Cancer (https://cancer.jmir.org), 10.11.2023.

Références

Bone Marrow Transplant. 2018 Jul;53(7):826-831
pubmed: 29367708
Blood. 2011 Apr 28;117(17):4651-7
pubmed: 21355084
J Cancer Surviv. 2018 Aug;12(4):560-570
pubmed: 29730827
Bone Marrow Transplant. 2020 Mar;55(3):641-648
pubmed: 31700138
BMC Cancer. 2022 Apr 30;22(1):475
pubmed: 35490223
Cyberpsychol Behav Soc Netw. 2013 Sep;16(9):708-13
pubmed: 23679571
Cancers (Basel). 2021 May 30;13(11):
pubmed: 34070773
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):655-661
pubmed: 34889363
Biol Blood Marrow Transplant. 2018 Nov;24(11):2285-2292
pubmed: 30031937
J Patient Rep Outcomes. 2020 Sep 1;4(1):74
pubmed: 32870420
Blood. 2014 Jul 17;124(3):354-62
pubmed: 24914137
Haematologica. 2018 Sep;103(9):1535-1541
pubmed: 29858386
Pediatr Transplant. 2014 May;18(3):302-9
pubmed: 24483231
Inflamm Bowel Dis. 2017 Jul;23(7):1057-1064
pubmed: 28410343
JMIR Cancer. 2022 Jun 13;8(2):e35930
pubmed: 35699985
Ther Adv Hematol. 2013 Dec;4(6):366-78
pubmed: 24319572
Curr Rev Musculoskelet Med. 2017 Mar;10(1):141-145
pubmed: 28110391
Ther Adv Hematol. 2018 Jan;9(1):21-46
pubmed: 29317998
ERJ Open Res. 2019 Feb 11;5(1):
pubmed: 30775374
Bone Marrow Transplant. 2018 Nov;53(11):1401-1415
pubmed: 29872128
Expert Opin Ther Targets. 2021 Sep;25(9):761-771
pubmed: 34669521
Bone Marrow Transplant. 2006 Aug;38(4):305-10
pubmed: 16819438
Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63
pubmed: 22510384
BMC Neurol. 2021 Jan 4;21(1):2
pubmed: 33397315
ERJ Open Res. 2021 Aug 02;7(3):
pubmed: 34350285
J Med Internet Res. 2020 Sep 21;22(9):e18306
pubmed: 32955443
BMJ Support Palliat Care. 2012 Dec;2(4):344-50
pubmed: 24654219
Front Oncol. 2022 May 20;12:863641
pubmed: 35719996
Health Qual Life Outcomes. 2021 Jan 7;19(1):11
pubmed: 33413414
Front Immunol. 2021 Nov 17;12:760199
pubmed: 34868001
Clin Transplant. 2013 Jan-Feb;27(1):E1-2
pubmed: 23215823
Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):283-7
pubmed: 25455279
Blood Adv. 2020 Dec 22;4(24):6283-6290
pubmed: 33351121
J Med Internet Res. 2021 May 12;23(5):e17917
pubmed: 33978589
Bone Marrow Transplant. 2021 Jun;56(6):1248-1256
pubmed: 33514922
Dermatol Clin. 2019 Oct;37(4):569-582
pubmed: 31466596
Oncologist. 2022 Aug 5;27(8):685-693
pubmed: 35443042
Bone Marrow Transplant. 2018 Apr;53(4):490-494
pubmed: 29330389
Biol Blood Marrow Transplant. 2019 Nov;25(11):2234-2242
pubmed: 31260800
Popul Health Manag. 2020 Oct;23(5):350-360
pubmed: 32897820
Bone Marrow Transplant. 2021 Jul;56(7):1651-1664
pubmed: 33623153
Psychooncology. 2014 Nov;23(11):1307-13
pubmed: 24830676
Lancet Haematol. 2020 Feb;7(2):e157-e167
pubmed: 32004485
J Med Internet Res. 2022 Jan 7;24(1):e30379
pubmed: 34994706
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383

Auteurs

Zinaida Perić (Z)

School of Medicine, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia.

Grzegorz Basak (G)

Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

Christian Koenecke (C)

Hannover Medical School, Hannover, Germany.

Ivan Moiseev (I)

RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation.

Jyoti Chauhan (J)

Novartis Healthcare Pvt Ltd, Hyderabad, India.

Sathyaraj Asaithambi (S)

Novartis Healthcare Pvt Ltd, Hyderabad, India.

Alexandros Sagkriotis (A)

Novartis Pharmaceuticals AG, Basel, Basel, Switzerland.
Gilead Sciences Europe Ltd, Uxbridge, United Kingdom.

Sibel Gunes (S)

Novartis Pharmaceuticals AG, Basel, Basel, Switzerland.

Olaf Penack (O)

Department of Hematology, Oncology, and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Classifications MeSH